TY - JOUR
T1 - Glioblastoma Therapy in the Age of Molecular Medicine
AU - Medeiros Geraldo, Luiz Henrique
AU - Garcia, Celina
AU - Carvalho da Fonseca, Anna Carolina
AU - Feijo Dubois, Luiz Gustavo
AU - Leite de Sampaio e Spohr, Tania Cristina
AU - Matias, Diana
AU - de Camargo Magalhaes, Eduardo Sabino
AU - do Amaral, Rackele Ferreira
AU - da Rosa, Barbara Gomes
AU - Grimaldi, Izabella
AU - Leser, Felipe Sceanu
AU - Janeiro, Jose Marcos
AU - Macharia, Lucy
AU - Wanjiru, Caroline
AU - Pereira, Claudia Maria
AU - Moura-Neto, Vivaldo
AU - Freitas, Catarina
AU - Souza Lima, Flavia Regina
PY - 2019/1
Y1 - 2019/1
N2 - Glioblastoma (GBM) is the most common and fatal primary malignant brain tumor. Despite advances in the understanding of the biology of gliomas, little has changed in the treatment of these tumors in the past decade. Phase III clinical trials showed no benefit for the use of bevacizumab in newly diagnosed patients, leading to a renewed search for new antiangiogenic drugs, as well as immunotherapeutic approaches, including checkpoint inhibitors, chimeric antigen receptor T cells, and intracerebral CpG-oligodeoxynucleotides. The emerging role of infiltrating microglia and macrophages, and of metabolic alterations, is also being taken into account in preclinical research and drug development. In this review, we discuss progress in the search for new therapeutic strategies, particularly approaches focusing on the tumor microenvironment.
AB - Glioblastoma (GBM) is the most common and fatal primary malignant brain tumor. Despite advances in the understanding of the biology of gliomas, little has changed in the treatment of these tumors in the past decade. Phase III clinical trials showed no benefit for the use of bevacizumab in newly diagnosed patients, leading to a renewed search for new antiangiogenic drugs, as well as immunotherapeutic approaches, including checkpoint inhibitors, chimeric antigen receptor T cells, and intracerebral CpG-oligodeoxynucleotides. The emerging role of infiltrating microglia and macrophages, and of metabolic alterations, is also being taken into account in preclinical research and drug development. In this review, we discuss progress in the search for new therapeutic strategies, particularly approaches focusing on the tumor microenvironment.
KW - EPIDERMAL-GROWTH-FACTOR
KW - CANCER STEM-CELLS
KW - NEWLY-DIAGNOSED GLIOBLASTOMA
KW - CENTRAL-NERVOUS-SYSTEM
KW - PHASE-II TRIAL
KW - FACTOR RECEPTOR
KW - T-CELLS
KW - RECURRENT GLIOBLASTOMA
KW - HUMAN GLIOMA
KW - TUMOR-CELL
U2 - 10.1016/j.trecan.2018.11.002
DO - 10.1016/j.trecan.2018.11.002
M3 - Review article
SN - 2405-8025
VL - 5
SP - 46
EP - 65
JO - Trends in cancer
JF - Trends in cancer
IS - 1
ER -